Skip to main content
IAS 2023

Prizes and awards

pattern above-s

CIPHER Grant Programme: Annual programme

The CIPHER Grant Programme provides a unique opportunity for early-stage investigators to address research gaps in paediatric and adolescent HIV in settings where HIV resources are limited. The intention is to promote evidence-based HIV policies and programmes in these settings. The grants are for up to USD 150,000 for two years. The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) is an initiative of the International AIDS Society; this programme is made possible through support from CIPHER Founding Sponsor ViiV Healthcare.

Read more
 

IAS 2023 recipients:
 

  • Tariro Dianah Chawana

  • Christina Alexandra Giulia Laurenzi

  • Yélamikan Frank Serge Touré

pattern above-s

IAS CPP Advocacy-for-Cure Academy Fellowship Prize: Annual prize

The IAS Advocacy-for-Cure Academy, organized in partnership with AVAC, awards fellowships to advocates and peer educators interested in advancing the HIV cure field in countries with limited resources for HIV cure research. This USD 2,000 annual prize, sponsored by the IAS Corporate Partnership Programme (CPP), is presented to one outstanding fellow based on their engagement during the academy, collaborative spirit and continued engagement in the HIV cure field.
 

IAS 2023 recipient:
 

  • Deborah Leticia Akumu

pattern above-s

The Journal of the International AIDS Society (JIAS) Impact Awards acknowledge high-impact publications from the previous year, as determined by the journal’s Editorial Board members and Deputy Editors. Selections are made based on a combination of public health importance, downloads and citations. Three awards will be announced at IAS 2023.

An Impact Award will go to the manuscript’s first author and will cover the registration fee for a future conference (AIDS 2024 or IAS 2025). IAS – the International AIDS Society – sponsors the JIAS Impact Awards.
 

IAS 2023 recipients:
 

  • Kelika Konda and Thiago Torres

  • Nicole McCann

  • Yunia Mayanja

pattern above-s

Me and My Healthcare Provider

The Me and My Healthcare Provider campaign is driven by key populations affected by HIV, giving them an opportunity to acknowledge the contributions of healthcare providers who have made a tangible difference in their lives. By highlighting their stories, the campaign encourages replication and empowers other healthcare providers to raise their voices against stigma.

At IAS 2023, IAS – the International AIDS Society – in partnership with Gilead Sciences, will announce the winning Champions of the Me and My Healthcare Provider campaign from Brazil, Hong Kong, Mexico and Taiwan. This distinguished award celebrates frontline healthcare workers who have made a difference in the lives of people living with HIV by delivering stigma-free HIV prevention, treatment and care services.
 

IAS 2023 recipients:
 

  • Wandson Padilha

  • Lívia Medeiros Rodrigo Moreira

  • Jesimiel Correa Barros

  • Iuçara Medeiros

  • Carlos Alberto López Zaragoza

  • Carolina Limón Hernández

  • Miguel Ángel Herrera Herrera

  • Roy Nelson Cecilio Mendoza

  • Chien-Yu Cheng

  • Peing Chuang

  • Yi-Hui Wu

  • Wen-Wei Ku

  • Po-Ang Chen

  • Tsang Tak Yin

  • Wilson Lam

  • Chan Shan

  • To Ki Wai

pattern above-s

MSD/IAS Prize for Research in Long-Acting HIV Prevention and Treatment: Annual prize

IAS – the International AIDS Society – and Merck Sharpe & Dohme (MSD) award a co-partnered prize for the top-scoring abstracts at IAS 2023 with a focus on long-acting HIV prevention and treatment. The first edition of this prize in long-acting HIV prevention and treatment will recognize the highest-scoring abstracts with a focus on the following areas: development of long-acting prevention options; long-acting treatment options; optimal strategies for delivery of long-acting PrEP and ART technologies; studies on ART in acute, first- and second line therapies; efficacy, adherence, adverse reactions and complications; key populations; novel trial design and monitoring strategies. The prize (USD 10,000 per recipient) is awarded to the four highest-scoring abstracts. It is funded by MSD.
 

IAS 2023 recipients:
 

  • Amanda R. Liberman

  • Claire Pedersen

  • Trang N. Nguyen

  • Vamsi Vasireddy

Read more

Eligible candidates are presenting authors of regular and late-breaker abstracts submitted to IAS 2023 that meet the following criteria:

  • The abstract has been accepted as an oral presentation or for the poster exhibition.
  • The research demonstrates innovation, originality, rationale and quality.
  • The abstract presents data on long-acting HIV prevention and treatment.
pattern above-s

IAS/ANRS Lange/van Tongeren Prizes for Young Investigators: Annual prizes

The five USD 2,000 IAS/ANRS Lange/van Tongeren Prizes for Young Investigators are jointly funded by IAS – the International AIDS Society – and ANRS | Emerging Infectious Diseases (France) to support young researchers who demonstrate innovation, originality, rationale and quality in HIV research. The prizes are granted to the top-scoring abstract in each of the six tracks: Track A (basic science); Track B (clinical science); Track C (epidemiology and prevention science); Track D (social and behavioural sciences); and Track E (implementation science, economics, systems and synergies). In 2015, the Young Investigator Prize was permanently renamed in memory of Joep Lange and Jacqueline van Tongeren.

Previous winners
 

IAS 2023 recipients:
 

  • Paula M Cevaal

  • Annemarie Glassey

  • Mayara Secco Torres da Silva

  • Carrie Lyons

  • Stephanie D Roche

 

Read more

Eligible candidates are presenting authors of abstracts submitted to IAS 2023 that meet the following criteria:

  • The abstract has been accepted as an oral presentation or for the poster exhibition.
  • The research demonstrates innovation, originality, rationale and quality.
  • The presenting author is under 35 years of age.

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.